Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPP1: MDMA-Assisted Therapy for Severe PTSD
NCT03537014Phase 3Completed
- Sponsor
- Lykos Therapeutics
- Start
- Nov 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Lykos Therapeutics. Started Nov 2018; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03537014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03537014.